The trial, which was completed in 2001, is popularly known as the PROWESS (recombinant human activated protein C worldwide evaluation in severe sepsis) trial.[17] Patients either received drotrecogin alfa at the rate of 24 mcg /kg/hour or placebo for 96 hours of total infusion time. Here, PROC is linked to Sepsis.